Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279 Consecutive patients with head and ...
Genmab will stop development of its experimental antibody therapy to treat cancer that was in late-stage trials, the Danish ...
“This collaboration underscores our belief in zanzalintinib’s potential to drive patient benefit in combination with immunotherapy or targeted therapy in HNSCC and RCC indications that have unmet ...
10d
CoRegen Appoints Globally Recognized Surgeon-Scientist Bert O’Malley Jr. to its Board of Directors
HOUSTON, Dec. 22, 2025 (GLOBE NEWSWIRE) -- CoRegen, Inc., a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of solid tumor cancer, today ...
In more recent decades, HPV has been shown as a risk factor for developing head and neck cancer. Head and neck cancer covers everything from throat, tongue, and tonsil cancer to laryngeal, mouth, and ...
The goal of the Head and Neck Oncology/Endocrine team in the UAB Department of Otolaryngology is to provide outstanding patient care in a compassionate, innovative, and user-friendly manner. The range ...
Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain head and neck cancers from returning. Continuous use of Keytruda—both ...
Adding neoadjuvant and adjuvant pembrolizumab to the standard of care significantly improved event-free survival in patients with previously untreated, locally advanced head and neck squamous cell ...
Head and neck cancers represent 4% of U.S. cancer cases, with significant mortality rates, highlighting the need for awareness and early detection. These cancers affect multiple anatomical sites, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback